# A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

> **NCT05588440** · PHASE1,PHASE2 · TERMINATED · sponsor: **Oncternal Therapeutics, Inc** · enrollment: 9 (actual)

## Conditions studied

- Relapsed/Refractory Aggressive B-Cell Malignancies

## Interventions

- **BIOLOGICAL:** ONCT-808
- **DRUG:** Bridging Therapy

## Key facts

- **NCT ID:** NCT05588440
- **Lead sponsor:** Oncternal Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-09
- **Primary completion:** 2024-09-12
- **Final completion:** 2024-09-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Based on the available clinical data and capital requirements for continued development, the Company has decided to terminate this study.
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05588440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05588440, "A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05588440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*